Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Receivables (2021 - 2024)

Zentalis Pharmaceuticals has reported Receivables over the past 2 years, most recently at $5.0 million for Q4 2024.

  • For Q4 2024, Receivables changed N/A year-over-year to $5.0 million; the TTM value through Dec 2024 reached $5.0 million, changed N/A, while the annual FY2024 figure was $5.0 million, N/A changed from the prior year.
  • Receivables for Q4 2024 was $5.0 million at Zentalis Pharmaceuticals, up from $2.4 million in the prior quarter.
  • Over five years, Receivables peaked at $5.0 million in Q4 2024 and troughed at $2.4 million in Q4 2021.